GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis

Supportive Care in Cancer

Volumn 23, Issue 3, 2015, Pages 841-849

  Coleman, Elizabeth Ann ^a   Lee, Jeannette Y ^c   Erickson, Stephen W ^c   Goodwin, Julia A ^b   Sanathkumar, Naveen ^a   Raj, Vinay R ^a   Zhou, Daohong ^a   McKelvey, Kent D ^d   Apewokin, Senu ^a   Stephens, Owen ^a   Enderlin, Carol A ^a   Vangsted, Annette Juul ^d   Reed, Patty J ^a   Anaissie, Elias J ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d ROSKILDE HOSPITAL   (Denmark)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy induced oral mucositis; Genetic variants; GWAS; Multiple myeloma; Oral mucositis; SNPs

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; C REACTIVE PROTEIN; CISPLATIN; COLLAGENASE 3; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; MELPHALAN; SERUM ALBUMIN; THALIDOMIDE; VINCRISTINE;

ADULT; ALBUMIN BLOOD LEVEL; ALDH1A1 GENE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY MASS; BODY SURFACE; CANCER CHEMOTHERAPY; CEP192 GENE; CONTROLLED STUDY; CPEB1 GENE; DHRS7C GENE; DMRTA1 GENE; DRUG MEGADOSE; FBN2 GENE; FEMALE; FLJ35282 GENE; GENE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; JPH3 GENE; LINC00692 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL MUCOSITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; AGED; AUTOTRANSPLANTATION; CHEMICALLY INDUCED; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INDUCTION CHEMOTHERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; STATISTICS AND NUMERICAL DATA; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STOMATITIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84922185101     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2406-x     Document Type: Article

References (37)

1. Barlogie B, Shaughnessy J, Tricot G et al (2004) Treatment of multiple myeloma. Blood 103(1):20–32. doi:10.1182/blood-2003-04-1045
2. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 102(7):2684–2691. doi:10.1182/blood-2002-10-3250
3. Blijlevens N, Schwenkglenks M, Bacon P et al (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy. European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26(9):1519–1525. doi:10.1200/JCO.2007.13.6028
4. Clarkson JE, Worthington HV, Furness S et al (2010) Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 8, CD001973. doi:10.1002/14651858.CD001973.pub4
5. McCann S, Schwenkglenks M, Bacon P et al (2009) The prospective oral mucositis audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant 43(2):141–147. doi:10.1038/bmt.2008.299
6. Epstein JB (2007) Mucositis in the cancer patient and immunosuppressed host. Infect Dis Clin North Am 21(2):503–522. doi:10.1016/j.idc.2007.03.003, vii
7. Sharma SK, Handoo A, Choudhary D, Dhamija G, Gupta N (2013) Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma. World J Gastroenterol 19(5):784–785. doi:10.3748/wjg.v19.i5.784, PMCID: PMC3574610. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574610/pdf/WJG-19-784.pdf
8. Murphy BA (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5(9 Suppl 4):13–21, http://www.oncologypractice.com/jso/journal/articles/0509s413.pdf
9. Tsirigotis P, Triantafyllou K, Girkas K et al (2008) Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 42(5):337–343. doi:10.1038/bmt.2008.168
10. Grazziutti ML, Dong L, Miceli MH et al (2006) Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 38(7):501–506. doi:10.1038/sj.bmt.1705471
11. Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoetic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030. doi:10.1056/NEJMoa053583
12. Barlogie B, Anaissie E, van Rhee F et al (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3. Br J Haematol 138(2):176–185. doi:10.1111/j.1365-2141.2007.06639.x
13. Anaissie EJ et al (2010) Comparing toxicities and survival outcomes with total therapy 4 (TT4) for 70-gene (R70)-defined low-risk multiple myeloma (MM) to results obtained with Total Therapy 3 Protocols TT3A and TT3B. Blood (ASH Annu Meet Abstr) 116(21), Abstract 368, http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/368?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=368+&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT
14. Mosteller RD (1987) Simplified calculation of body surface area. N Engl J Med 317(17):1098. doi:10.1056/NEJM198710223171717
15. Common Terminology Criteria for Adverse Events (CTCAE) version 4. http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf
16. Levey AS, Greene T, Kusek JW et al (2000) A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 11:A0828, 155A
17. Cochran WG (1954) Some methods for strengthening the common chi-squared tests. Biometrics (Int Biom Soc) 10(4):417–451. doi:10.2307/3001616
18. Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics (Int Biom Soc) 11(3):375–386. doi:10.2307/3001775
19. Benjamimi Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc B 57(1):289–300, http://www.jstor.org/stable/2346101
20. Guttman M, Rinn JL (2012) Modular regulatory principles of large non-coding RNAs. Nature 482(7385):339–346. doi:10.1038/nature10887
21. Chen G, Qiu C, Zhang Q et al (2013) Genome-wide analysis of human SNPs at long intergenic noncoding RNAs. Hum Mutat 34(2):338–344. doi:10.1002/humu.22239
22. Sonis ST, Antin JH, Tedaldi MW, Alterovitz G (2013) SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 19(7):721–727. doi:10.1111/odi.12146
23. Sonis ST (2011) Oral mucositis. Anti Cancer Drugs 22(7):607–612. doi:10.1097/CAD.0b013e3283462086
24. Haynes SL, Shuttleworth CA, Kielty CM (1997) Keratinocytes express fibrillin and assemble microfibrils: implications for dermal matrix organization. Br J Dermatol 137(1):17–23. doi:10.1046/j.1365-2133.1997.1762185.x
25. Davis MR, Summers KM (2012) Structure and function of the mammalian fibrillin gene family: Implications for human connective tissue diseases. Mol Genet Metab 107(4):635–647. doi:10.1016/j.ymgme.2012.07.023
26. Nistala H, Lee-Arteaga S, Smaldone S et al (2010) Fibrillin-1 and -2 differently modulate endogenous TGF-β and BMP bioavailability during bone formation. J Cell Biol 190(6):1107–1121. doi:10.1083/jcb.201003089
27. Ben-Lulu S, Pollak Y, Mogilner J et al (2012) Dietary transforming growth factor-beta 2 (TGF-β2) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat. PLoS One 7(9):e45221. doi:10.1371/journal.pone.0045221
28. de Koning BAE, Philipsen-Geerling B, Hoijer M et al (2007) Protection against chemotherapy induced mucositis by TGF-β2 in childhood cancer patients: results from a randomized cross-over study. Pediatr Blood Cancer 48(5):532–539. doi:10.1002/pbc.20910
29. Foncuberta MC, Cagnoni PJ, Brandts CH et al (2001) Topical transforming growth factor TGF-β3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 24(4):384–388. doi:10.1097/00002371-200107000-00014
30. Bian HG, Li LF et al (2013) Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med 19(4):421–428. doi:10.1038/nm.3118
31. Uitto VJ, Airola K, Vaalamo M et al (1998) Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol 152(6):1489–1499, PMC1858431
32. Hattori N, Mochizuki S, Kishi K et al (2009) MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing. Am J Pathol 175(2):533–546. doi:10.2353/ajpath.2009.081080
33. Toriseva M, Laato M, Carpen O et al (2012) MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability. PLoS One 7(8):e42596. doi:10.1371/journal.pone.0042596
34. Pinto N, Ludeman SM, Dolan ME (2009) Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10(12):1897–1903. doi:10.2217/pgs.09.134
35. Hassan M, Andersson BS (2013) Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 14(1):75–87. doi:10.2217/pgs.12.185
36. Lu B, Tigchelaar W, Ruifrok W et al (2012) DHRS7c, a novel cardiomyocyte-expressed gene that is down-regulated by adrenergic stimulation and in heart failure. Eur J Heart Fail 14(1):5–13. doi:10.1093/eurjhf/hfr152
37. Pearson TA, Manolio TA (2008) How to interpret a genome-wide association study. JAMA 299(11):1335–1344. doi:10.1001/jama.299.11.1335